Amisulpride (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amisulpride" in Italian language version.

refsWebsite

Global rank Italian rank

19doi.org

2^nd place

7^th place

18nih.gov

4^th place

9^th place

3oadoi.org

799^th place

22^nd place

3torrinomedica.it

low place

2,002^nd place

2psychiatrictimes.com

9,815^th place

low place

2fda.gov

447^th place

644^th place

2thelancet.com

2,393^rd place

2,216^th place

1psychiatryonline.org

4,032^nd place

3,374^th place

1springer.com

274^th place

393^rd place

1acs.org

1,248^th place

1,065^th place

1elsevier.com

610^th place

820^th place

1omicsonline.com

low place

1oup.com

485^th place

613^th place

1my-personaltrainer.it

low place

690^th place

1medinews.net

low place

1web.archive.org

1^st place

1mja.com.au

low place

7,873^rd place

1meamedica.it

low place

acs.org

pubs.acs.org

(EN) Vincent Grattan, Andrew R. Vaino e Zachary Prensky, Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D 2 and D 3 , while R Enantiomers Engage 5-HT 7, in ACS Omega, vol. 4, n. 9, 27 agosto 2019, pp. 14151–14154, DOI:10.1021/acsomega.9b02144. URL consultato il 26 marzo 2024.

doi.org

dx.doi.org

Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G., A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers., in Human Psychopharmacology, vol. 17, n. 1, 2002, pp. 1–13, DOI:10.1002/hup.320, PMID 12404702.
L. Pani e G. L. Gessa, The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia, in Molecular Psychiatry, vol. 7, n. 3, 2002, pp. 247–253, DOI:10.1038/sj.mp.4001040. URL consultato il 24 febbraio 2023.
Lecrubier, Y. et al., Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia, in Neuropsychobiology, vol. 44, n. 1, 2001, pp. 41–46, DOI:10.1159/000054913, PMID 11408792.
(EN) Nick Zagorski, Amisulpride: What’s Old Can Be New in the United States, in Psychiatric News, vol. 56, n. 7, 1º luglio 2021, pp. appi.pn.2021.4.11, DOI:10.1176/appi.pn.2021.4.11. URL consultato il 24 febbraio 2023.
(EN) Atheir I. Abbas, Peter B. Hedlund e Xi-Ping Huang, Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo, in Psychopharmacology, vol. 205, n. 1, 2009-07, pp. 119–128, DOI:10.1007/s00213-009-1521-8. URL consultato il 24 febbraio 2023.
(EN) Vincent Grattan, Andrew R. Vaino e Zachary Prensky, Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D 2 and D 3 , while R Enantiomers Engage 5-HT 7, in ACS Omega, vol. 4, n. 9, 27 agosto 2019, pp. 14151–14154, DOI:10.1021/acsomega.9b02144. URL consultato il 26 marzo 2024.
(EN) Michel Maitre, Charline Ratomponirina e Serge Gobaille, Displacement of [3H]γ-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics, in European Journal of Pharmacology, vol. 256, n. 2, 1994-04, pp. 211–214, DOI:10.1016/0014-2999(94)90248-8. URL consultato il 24 febbraio 2023.
(EN) Blomme A, Conraux L, Poirier P, Olivier A, Koenig JJ, Sevrin M, Durant F, George P, Amisulpride, Sultopride and Sulpiride: Comparison of Conformational and Physico-Chemical Properties, in Molecular Modeling and Prediction of Bioactivity, Springer US, 2000, pp. 404–405, DOI:10.1007/978-1-4615-4141-7_97, ISBN 978-1-4613-6857-1.
Ramakotaiah Mogili, Kanchanamala Kanala e Balasekhara Reddy Challa, Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study, in Scientia Pharmaceutica, vol. 79, n. 3, 2011, pp. 583–599, DOI:10.3797/scipharm.1105-12. URL consultato il 24 febbraio 2023.
M. Papp e J. Wieronska, Antidepressant-like activity of amisulpride in two animal models of depression, in Journal of Psychopharmacology (Oxford, England), vol. 14, n. 1, 1º marzo 2000, pp. 46–52, DOI:10.1177/026988110001400106. URL consultato il 19 aprile 2017.
K. Komossa, C. Rummel-Kluge; H. Hunger; F. Schmid; S. Schwarz; JI. Silveira da Mota Neto; W. Kissling; S. Leucht, Amisulpride versus other atypical antipsychotics for schizophrenia., in Cochrane Database Syst Rev, n. 1, 2010, pp. CD006624, DOI:10.1002/14651858.CD006624.pub2, PMID 20091599.
(EN) Stefan Leucht, Andrea Cipriani e Loukia Spineli, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in The Lancet, vol. 382, n. 9896, 14 settembre 2013, DOI:10.1016/S0140-6736(13)60733-3. URL consultato il 29 ottobre 2017.
Luca Pani, José M. Villagrán e Vassilis P. Kontaxakis, Practical issues with amisulpride in the management of patients with schizophrenia, in Clinical Drug Investigation, vol. 28, n. 8, 2008, pp. 465–477, DOI:10.2165/00044011-200828080-00001. URL consultato il 27 aprile 2019.
P. Kranke, L. Eberhart e J. Motsch, I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial, in BJA: British Journal of Anaesthesia, vol. 111, n. 6, 1º dicembre 2013, pp. 938–945, DOI:10.1093/bja/aet251. URL consultato il 19 aprile 2017.
Matteo Pardini, Silvia Guida e Alberto Primavera, Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study, in European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol. 21, n. 3, 1º marzo 2011, pp. 282–286, DOI:10.1016/j.euroneuro.2010.10.008. URL consultato il 19 aprile 2017.
(EN) Stefan Leucht, Andrea Cipriani e Loukia Spineli, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in The Lancet, vol. 382, n. 9896, 14 settembre 2013, DOI:10.1016/S0140-6736(13)60733-3. URL consultato il 19 aprile 2017.
Elvis Henrique Santos Andrade, Pedro Mario Pan e Paula F. Ramalho da Silva, New Insights in the Management of Antipsychotics in the Treatment of Schizophrenia in a Patient with Prolactinoma: A Case Report and Review of the Literature, in Case Reports in Medicine, vol. 2010, 2010, DOI:10.1155/2010/573252. URL consultato il 25 luglio 2019.
Pattath Narayanan Suresh Kumar e Arun Gopalakrishnan, Extrapyramidal Side Effects with Low Dose Amisulpride: A Report of Two Cases, in Indian Journal of Psychological Medicine, vol. 38, n. 5, 1º settembre 2016, pp. 480–482, DOI:10.4103/0253-7176.191391. URL consultato il 19 aprile 2017.
Faruk Uguz, Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety, in Journal of Clinical Psychopharmacology, vol. 36, n. 3, 1º giugno 2016, pp. 244–252, DOI:10.1097/JCP.0000000000000491. URL consultato il 19 aprile 2017.

elsevier.com

linkinghub.elsevier.com

(EN) Michel Maitre, Charline Ratomponirina e Serge Gobaille, Displacement of [3H]γ-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics, in European Journal of Pharmacology, vol. 256, n. 2, 1994-04, pp. 211–214, DOI:10.1016/0014-2999(94)90248-8. URL consultato il 24 febbraio 2023.

fda.gov

accessdata.fda.gov

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, su accessdata.fda.gov. URL consultato il 13 ottobre 2021.
U.S. Food and Drug Administration (FDA), Barhemsys (amisulpride) injection, for intravenous use (PDF), febbraio 2020.

meamedica.it

Amisulpride | Farmaci: Esperienze ed effetti collaterali, su meamedica.it. URL consultato il 16 aprile 2019.

medinews.net

Amisulpiride | MediNews.net, su medinews.net. URL consultato il 26 agosto 2017.

mja.com.au

Isbister, G.; Murray, L.; John, S.; Hackett, L.; Haider, T.; O'Mullane, P.; Gosselin, S.; Daly, F., Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes, in Medical Journal of Australia, vol. 184, n. 7, 2006, pp. 354–356, PMID 16584372.

my-personaltrainer.it

(EN) Solian - Foglietto Illustrativo, su my-personaltrainer.it. URL consultato il 19 aprile 2017.

nih.gov

ncbi.nlm.nih.gov

Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G., A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers., in Human Psychopharmacology, vol. 17, n. 1, 2002, pp. 1–13, DOI:10.1002/hup.320, PMID 12404702.
Lecrubier, Y. et al., Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia, in Neuropsychobiology, vol. 44, n. 1, 2001, pp. 41–46, DOI:10.1159/000054913, PMID 11408792.
M. Amore, MC. Jori, Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study., in Int Clin Psychopharmacol, vol. 16, n. 6, novembre 2001, pp. 317-24, PMID 11712619.
M. Papp, J. Wieronska, Antidepressant-like activity of amisulpride in two animal models of depression., in J Psychopharmacol, vol. 14, n. 1, marzo 2000, pp. 46-52, PMID 10757253.
L. Ravizza, Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators., in J Psychopharmacol, vol. 13, n. 3, 1999, pp. 248-54, PMID 10512080.
P. Boyer, Y. Lecrubier; A. Stalla-Bourdillon; O. Fleurot, Amisulpride versus amineptine and placebo for the treatment of dysthymia., in Neuropsychobiology, vol. 39, n. 1, 1999, pp. 25-32, PMID 9892856.
M. Papp e J. Wieronska, Antidepressant-like activity of amisulpride in two animal models of depression, in Journal of Psychopharmacology (Oxford, England), vol. 14, n. 1, 1º marzo 2000, pp. 46–52, DOI:10.1177/026988110001400106. URL consultato il 19 aprile 2017.
E. Smeraldi, Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study, in Journal of Affective Disorders, vol. 48, n. 1, febbraio 1998, pp. 47–56. URL consultato il 29 ottobre 2017.
K. Komossa, C. Rummel-Kluge; H. Hunger; F. Schmid; S. Schwarz; JI. Silveira da Mota Neto; W. Kissling; S. Leucht, Amisulpride versus other atypical antipsychotics for schizophrenia., in Cochrane Database Syst Rev, n. 1, 2010, pp. CD006624, DOI:10.1002/14651858.CD006624.pub2, PMID 20091599.
Luca Pani, José M. Villagrán e Vassilis P. Kontaxakis, Practical issues with amisulpride in the management of patients with schizophrenia, in Clinical Drug Investigation, vol. 28, n. 8, 2008, pp. 465–477, DOI:10.2165/00044011-200828080-00001. URL consultato il 27 aprile 2019.
Matteo Pardini, Silvia Guida e Alberto Primavera, Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study, in European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol. 21, n. 3, 1º marzo 2011, pp. 282–286, DOI:10.1016/j.euroneuro.2010.10.008. URL consultato il 19 aprile 2017.
Elvis Henrique Santos Andrade, Pedro Mario Pan e Paula F. Ramalho da Silva, New Insights in the Management of Antipsychotics in the Treatment of Schizophrenia in a Patient with Prolactinoma: A Case Report and Review of the Literature, in Case Reports in Medicine, vol. 2010, 2010, DOI:10.1155/2010/573252. URL consultato il 25 luglio 2019.
Klementina Ružić, Tanja Grahovac e Mirjana Graovac, Hyperprolactinaemia with amisulpride, in Psychiatria Danubina, vol. 23, n. 1, 1º marzo 2011, pp. 92–94. URL consultato il 19 aprile 2017.
Isbister, G.; Murray, L.; John, S.; Hackett, L.; Haider, T.; O'Mullane, P.; Gosselin, S.; Daly, F., Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes, in Medical Journal of Australia, vol. 184, n. 7, 2006, pp. 354–356, PMID 16584372.
Pattath Narayanan Suresh Kumar e Arun Gopalakrishnan, Extrapyramidal Side Effects with Low Dose Amisulpride: A Report of Two Cases, in Indian Journal of Psychological Medicine, vol. 38, n. 5, 1º settembre 2016, pp. 480–482, DOI:10.4103/0253-7176.191391. URL consultato il 19 aprile 2017.
Faruk Uguz, Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety, in Journal of Clinical Psychopharmacology, vol. 36, n. 3, 1º giugno 2016, pp. 244–252, DOI:10.1097/JCP.0000000000000491. URL consultato il 19 aprile 2017.

pubmed.ncbi.nlm.nih.gov

L. Pani e G. L. Gessa, The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia, in Molecular Psychiatry, vol. 7, n. 3, 2002, pp. 247–253, DOI:10.1038/sj.mp.4001040. URL consultato il 24 febbraio 2023.
Ramakotaiah Mogili, Kanchanamala Kanala e Balasekhara Reddy Challa, Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study, in Scientia Pharmaceutica, vol. 79, n. 3, 2011, pp. 583–599, DOI:10.3797/scipharm.1105-12. URL consultato il 24 febbraio 2023.

oadoi.org

Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G., A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers., in Human Psychopharmacology, vol. 17, n. 1, 2002, pp. 1–13, DOI:10.1002/hup.320, PMID 12404702.
Lecrubier, Y. et al., Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia, in Neuropsychobiology, vol. 44, n. 1, 2001, pp. 41–46, DOI:10.1159/000054913, PMID 11408792.
K. Komossa, C. Rummel-Kluge; H. Hunger; F. Schmid; S. Schwarz; JI. Silveira da Mota Neto; W. Kissling; S. Leucht, Amisulpride versus other atypical antipsychotics for schizophrenia., in Cochrane Database Syst Rev, n. 1, 2010, pp. CD006624, DOI:10.1002/14651858.CD006624.pub2, PMID 20091599.

omicsonline.com

Mansoor Ahmad Dar, Rayees Ahmad Wani, Mushtaq Ahmad Margoob, Inaamul Haq, Arshad Hussain, Rajesh Kumar Chandel, Yasir Hassan Rather, MajidShafi Shah, Altaf Ahmad Malla, Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India (PDF).

oup.com

academic.oup.com

P. Kranke, L. Eberhart e J. Motsch, I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial, in BJA: British Journal of Anaesthesia, vol. 111, n. 6, 1º dicembre 2013, pp. 938–945, DOI:10.1093/bja/aet251. URL consultato il 19 aprile 2017.

psychiatrictimes.com

Kaplan, A., Psychotropic Medications Around the World, in Psychiatric Times, vol. 21, n. 5, 2004.
Psychotropic Medications Around the World, in PsychiatricTimes.

psychiatryonline.org

(EN) Nick Zagorski, Amisulpride: What’s Old Can Be New in the United States, in Psychiatric News, vol. 56, n. 7, 1º luglio 2021, pp. appi.pn.2021.4.11, DOI:10.1176/appi.pn.2021.4.11. URL consultato il 24 febbraio 2023.

springer.com

link.springer.com

(EN) Atheir I. Abbas, Peter B. Hedlund e Xi-Ping Huang, Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo, in Psychopharmacology, vol. 205, n. 1, 2009-07, pp. 119–128, DOI:10.1007/s00213-009-1521-8. URL consultato il 24 febbraio 2023.

thelancet.com

(EN) Stefan Leucht, Andrea Cipriani e Loukia Spineli, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in The Lancet, vol. 382, n. 9896, 14 settembre 2013, DOI:10.1016/S0140-6736(13)60733-3. URL consultato il 29 ottobre 2017.
(EN) Stefan Leucht, Andrea Cipriani e Loukia Spineli, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in The Lancet, vol. 382, n. 9896, 14 settembre 2013, DOI:10.1016/S0140-6736(13)60733-3. URL consultato il 19 aprile 2017.

torrinomedica.it

Amisulpride Eg, su torrinomedica.it. URL consultato il 16 gennaio 2012.
Deniban 50 Mg, su torrinomedica.it. URL consultato il 16 gennaio 2012.
Deniban 50 Mg, su torrinomedica.it. URL consultato il 16 gennaio 2012.

web.archive.org

Glines, Hyperprolactinemia and antipsycotics (PDF). URL consultato il 20 aprile 2019 (archiviato dall'url originale il 23 novembre 2018).